Clinical Trial: A Study of MG-K10 in Chronic Spontaneous Urticaria

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07546487) titled 'A Study of MG-K10 in Chronic Spontaneous Urticaria' on March 19.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor control of second-generation H1 antihistamines.

Study Start Date: April 14

Study Type: INTERVENTIONAL

Condition: Chronic Spontaneous Urticaria (CSU)

Intervention: BIOLOGICAL: MG-K10 Humanized Monoclonal Antibody Injection

Administer once every 4 weeks, with an initial dose of 600mg (4.0 ml) and subsequent doses of 300mg (...